Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reata Discovery Inc.

This article was originally published in Start Up

Executive Summary

The crux of the discovery platform of Reata is an assay that reveals, basically in real time, the effect that small molecules are having on the folding behavior of proteins. Reata aims to harness this capability to identify compounds that beneficially influence proteins known to underlie diseases that are prone to misfolding in specific ways. In the case of Alzheimer's disease, Reata is looking at amyloid-beta , the principal component in the plaques found in the brains of AD patients, and at tau, which forms protein inclusions, or tangles, involved in a number of neurodegenerative diseases.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts